Emendo Biotherapeutics

EmendoBio is a private, pre-clinical stage biotech company developing a next-generation CRISPR gene editing platform called OMNI™. The platform is designed to discover and engineer novel nucleases with unique properties, aiming to achieve extreme precision, allele-specific editing, and the ability to target any gene in the genome. The company employs a collaborative business model, seeking partnerships with biopharma to integrate its platform into therapeutic development programs for complex genetic diseases. With a team of over 90 experts, EmendoBio is positioning itself to address the vast majority of genetic conditions, particularly dominant disorders, which require unprecedented editing specificity.

OMNI™ platform for discovering and engineering novel CRISPR nucleases with unique PAM specificities, optimized for extreme precision, allele-specific editing, and high activity with minimal off-target effects.

Operates in a crowded and fast-moving field of next-generation CRISPR editing, competing with companies like Prime Medicine, Beam Therapeutics, and Caribou Biosciences, as well as academic labs developing novel editors. Differentiation is claimed through a comprehensive platform for custom nuclease engineering and a disease-first approach.